Pharmacyte Biotech Inc (OTCMKTS:PMCB) stated that it is awaits results of its pivotal study that will enable the company to move forward with human clinical trials. The company has a strong line up of treatments and nowadays fetching attention of investors. It is set to heat into Phase II b clinical studies in advanced inoperable pancreatic cancer. It is expected to commence later this year in Australia.
Few weeks ago, Pharmacyte made headlines in the diabetes market after a report was issued highlighting that its Melligen cell line could result in insulin in diabetic mice. The data was positive indicating that the company is advancing with its studies focused on reversing the diabetes condition using live-cell encapsulation technology, termed as Cell in a Box®. In addition to the diabetes treatment research results, the investors are also keenly watching another research of the company.
The investors are looking forward for the result of a follow-up preclinical trial being carried out in the United States to cure the onset of malignant ascites fluid. The data of the highly anticipated trial could direct Pharmacyte right to the FDA requesting to commence a Phase I human clinical study to cure a “quality of life” symptom noticed in abdominal cancer patients. The trial is being conducted at the Translational Drug Development in Scottsdale, Arizona, under well-known oncologist, Dr. Daniel Von Hoff.
At the end of the trial, Pharmacyte stated that the treated mice showed a considerable survival benefit over those non-treated mice. Also, when the encapsulated cells and ifosfamide were used together with cisplatin in the initial trial, the survival rate was considerably enhanced. In last trading session, the stock price of Pharmacyte declined more than 3% to close the trading session at $0.159. The decline came at a share volume of 2.84 million compared to average share volume of 5.18 million.